BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)

Investigational New Drugs

Volumn 23, Issue 4, 2005, Pages 363-368

  Hofheinz, R D ^a   Porta, C ^b   Hartung, G ^c   Santoro, A ^d   Hanauske, A R ^e   Kutz, K ^f   Stern, A ^g   Barbieri, P ^h   Verdi, E ^h   Hehlmann, R ^a   Hochhaus, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e DEPARTMENT OF CARDIOLOGY   (Germany)

^f AccelPharm   (Switzerland)

^g Hesperion Ltd   (Switzerland)

^h Cell Therapeutics Inc (Europe)   (Italy)

Author keywords

BBR 3438; Gastric cancer; Second line therapy

Indexed keywords

2 [2 [(2 HYDROXYETHYL)AMINO]ETHYL] 5 [[2 (METHYLAMINO)ETHYL]AMINO]INDAZOLO[4,3 GH]ISOQUINOLIN 6(2H) ONE; ANTHRACYCLINE; LOPERAMIDE; MITOMYCIN C; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANGIOGRAPHY; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER RESEARCH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOPENIA; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; NAUSEA; NEUTROPENIA; NEUTROPHIL; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ETHANOLAMINES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUTROPENIA; PYRAZOLES; STOMACH NEOPLASMS; STOMATITIS;

EID: 22144439339     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-1445-z     Document Type: Article

References (12)

1. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ: Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30: 181-191, 2004
2. Swain SM, Vici P: The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: Expert panel review. J Cancer Res Clin Oncol 130: 1-7, 2004
3. Supino R, Polizzi D, Pavesi R, Pratesi G, Guano F, Capranico G, Palumbo M, Sissi C, Richter S, Beggiolin G, Menta E, Pezzoni G, Spinelli S, Torriani D, Carenini N, Dal Bo L, Facchinetti F, Tortoreto M, Zunino F: A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts. Oncology 61: 234-242, 2001
4. Behringer DM, Engelhart R, Hofheinz R-D, Hochhaus A, Herrmann R, Stern A, Camboni G, Bernareggi A: Phase I dose escalation study on the tolerability and activity of BBR 3438 in patients with advanced solid tumors. Eur J Cancer 38(Suppl): 23 (Abstr 82P), 2002
5. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138-1147, 1997
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000
7. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL 3rd, Winn RJ, Wozniak AJ, Somerfield MR: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18: 3558-3585, 2000
8. Simon R: Optimal two-stage designs for phase II clinical trials. Contr Clin Trials 10: 1-10, 1989
9. Workman P: Infusional anthracyclines: Is slower better? If so, why? Ann Oncol 3: 591, 1992
10. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M: Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrextae in advanced esophagogastric cancer. J Clin Oncol 15: 261-267, 1997
11. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma, Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253: 2061-2067, 1985
12. Graziano F, Catalano V, Baldelli AM, Giordani P, Testa E, Lai V, Catalano G, Battelli N, Cascinu S: A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 11: 1263-1266, 2000